BLGO — BioLargo Balance Sheet
0.000.00%
- $50.98m
- $47.51m
- $17.78m
- 16
- 22
- 68
- 26
Annual balance sheet for BioLargo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.716 | 0.962 | 1.85 | 3.54 | 3.55 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.484 | 0.513 | 1.06 | 2.61 | 3.17 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1.5 | 1.8 | 3.15 | 6.36 | 7.14 |
| Net Property, Plant And Equipment | 0.401 | 0.514 | 1.15 | 1.75 | 3.19 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 4.94 | 3.02 | 4.86 | 8.21 | 10.5 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.54 | 1.37 | 1.58 | 2.71 | 2.65 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.08 | -1.63 | -0.02 | 1.36 | 1.66 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 3.86 | 4.65 | 4.88 | 6.84 | 8.85 |
| Total Liabilities & Shareholders' Equity | 4.94 | 3.02 | 4.86 | 8.21 | 10.5 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |